Mangoceuticals (MGRX)
Market Price (3/30/2026): $0.4487 | Market Cap: $5.2 MilSector: Health Care | Industry: Health Care Technology
Mangoceuticals (MGRX)
Market Price (3/30/2026): $0.4487Market Cap: $5.2 MilSector: Health CareIndustry: Health Care Technology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -71% | Weak multi-year price returns2Y Excs Rtn is -104%, 3Y Excs Rtn is -161% | Penny stockMkt Price is 0.5 |
| Megatrend and thematic driversMegatrends include Health & Wellness Trends, Digital Health & Telemedicine, and E-commerce & DTC Adoption. Themes include Nutritional Supplements, Show more. | Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 11% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -20 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -4297% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -38%, Rev Chg QQuarterly Revenue Change % is -37% | ||
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 268% | ||
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -1264%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -1264% | ||
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -355% | ||
| High stock price volatilityVol 12M is 181% | ||
| Key risksMGRX key risks include [1] severe financial distress and a high probability of bankruptcy, Show more. |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -71% |
| Megatrend and thematic driversMegatrends include Health & Wellness Trends, Digital Health & Telemedicine, and E-commerce & DTC Adoption. Themes include Nutritional Supplements, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -104%, 3Y Excs Rtn is -161% |
| Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 11% |
| Penny stockMkt Price is 0.5 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -20 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -4297% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -38%, Rev Chg QQuarterly Revenue Change % is -37% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 268% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -1264%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -1264% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -355% |
| High stock price volatilityVol 12M is 181% |
| Key risksMGRX key risks include [1] severe financial distress and a high probability of bankruptcy, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Mangoceuticals (MGRX) stock has lost about 55% since 11/30/2025 because of the following key factors:
1. Significant Financial Losses and Going Concern Doubt. Mangoceuticals reported a net loss of $17.9 million for the nine months ended September 30, 2025, a substantial increase from $6.8 million in the prior year period. As of September 30, 2025, the company's recurring net losses and negative cash flows raised substantial doubt about its ability to continue as a going concern.
2. Shareholder Dilution from Capital Raises. On December 18, 2025, Mangoceuticals announced $2.5 million in registered direct and private placements. This contributed to substantial shareholder dilution experienced over the past year, resulting from capital raised through preferred stock, warrant exercises, and equity lines.
Show more
1. Significant Financial Losses and Going Concern Doubt. Mangoceuticals reported a net loss of $17.9 million for the nine months ended September 30, 2025, a substantial increase from $6.8 million in the prior year period. As of September 30, 2025, the company's recurring net losses and negative cash flows raised substantial doubt about its ability to continue as a going concern.
2. Shareholder Dilution from Capital Raises. On December 18, 2025, Mangoceuticals announced $2.5 million in registered direct and private placements. This contributed to substantial shareholder dilution experienced over the past year, resulting from capital raised through preferred stock, warrant exercises, and equity lines.
Show more
Stock Movement Drivers
Fundamental Drivers
The -56.1% change in MGRX stock from 11/30/2025 to 3/29/2026 was primarily driven by a -56.1% change in the company's P/S Multiple.| (LTM values as of) | 11302025 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.11 | 0.49 | -56.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | 27.4 | 12.0 | -56.1% |
| Shares Outstanding (Mil) | 12 | 12 | 0.0% |
| Cumulative Contribution | -56.1% |
Market Drivers
11/30/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| MGRX | -56.1% | |
| Market (SPY) | -5.3% | 20.8% |
| Sector (XLV) | -8.7% | -1.3% |
Fundamental Drivers
The -79.4% change in MGRX stock from 8/31/2025 to 3/29/2026 was primarily driven by a -73.7% change in the company's P/S Multiple.| (LTM values as of) | 8312025 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.36 | 0.49 | -79.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1 | 0 | -9.5% |
| P/S Multiple | 45.7 | 12.0 | -73.7% |
| Shares Outstanding (Mil) | 10 | 12 | -13.4% |
| Cumulative Contribution | -79.4% |
Market Drivers
8/31/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| MGRX | -79.4% | |
| Market (SPY) | 0.6% | 21.0% |
| Sector (XLV) | 5.2% | -4.7% |
Fundamental Drivers
The -88.2% change in MGRX stock from 2/28/2025 to 3/29/2026 was primarily driven by a -82.5% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 2282025 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.13 | 0.49 | -88.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1 | 0 | -38.2% |
| P/S Multiple | 11.0 | 12.0 | 9.2% |
| Shares Outstanding (Mil) | 2 | 12 | -82.5% |
| Cumulative Contribution | -88.2% |
Market Drivers
2/28/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| MGRX | -88.2% | |
| Market (SPY) | 9.8% | 16.3% |
| Sector (XLV) | -2.1% | 3.1% |
Fundamental Drivers
nullnull
Market Drivers
2/28/2023 to 3/29/2026| Return | Correlation | |
|---|---|---|
| MGRX | ||
| Market (SPY) | 69.4% | 8.5% |
| Sector (XLV) | 18.4% | 2.6% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| MGRX Return | - | - | -93% | -42% | -69% | -50% | -99% |
| Peers Return | -48% | -26% | 183% | 66% | 2% | -10% | 65% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -5% | 72% |
Monthly Win Rates [3] | |||||||
| MGRX Win Rate | - | - | 40% | 42% | 42% | 33% | |
| Peers Win Rate | 25% | 54% | 58% | 58% | 50% | 33% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 33% | |
Max Drawdowns [4] | |||||||
| MGRX Max Drawdown | - | - | -93% | -46% | -73% | -78% | |
| Peers Max Drawdown | -52% | -53% | -25% | -29% | -18% | -39% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -5% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: HIMS, LFMD.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 3/27/2026 (YTD)
How Low Can It Go
null
nullIn The Past
null
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Mangoceuticals (MGRX)
We plan to connect consumers to licensed healthcare professionals through our recently launched website at www.MangoRX.com for the provision of care via telehealth on our customer portal and plan to also provide access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations. To date, we have developed what we believe is a go-to-market strategy inclusive of product development, operations, marketing and advertising; however, we have not produced a significant amount of products and have generated only nominal revenues to date. We have identified men’s wellness telemedicine services and products as a growing sector in recent years and especially related to the areas of erectile dysfunction (“ED”) products. We have developed and are currently in the process of preparing to commercially market a new brand of ED product under the brand name “Mango.” This product is produced at a compounding pharmacy and is available to patients on the determination of a prescribing physician that the compounded drug is necessary for the individual patient. This product currently includes the following three ingredients: Tadalafil (the active ingredient in Cialis) and Oxytocin, which are used in U.S. Food and Drug Administration (“FDA”) approved drugs; and L-Arginine, an amino acid that is available as a dietary supplement. However, the fact that Tadalafil and Oxytocin are used in FDA approved drugs, and L-arginine is available as a dietary supplement, does not mean that these ingredients will prove safe when combined into a single formulation to treat ED. We currently offer two dosage levels of our Mango ED product and anticipate doctors prescribing a dosage based on the needs and medical history of the patient. Our Mango ED product currently includes the following amounts of the three ingredients discussed above: (1) Tadalafil (10 milligrams (mg)), Oxytocin (100 International units (IU)) and L-Arginine (50mg); and (2) Tadalafil (20mg), Oxytocin (100IU) and L-Arginine (50mg). Our Mango ED product has not been, and will not be, approved by the FDA and instead we plan to produce and sell our products, including our Mango ED product, under an exemption provided by Section 503A of the Federal Food, Drug, and Cosmetic Act, as discussed below. We are not aware of any clinical studies involving the administration of tadalafil sublingually at the doses we provide patients, or the compounding of tadalafil, oxytocin, and L-arginine to treat ED, as is contemplated by our ED product. We are, however, aware of other companies that are currently selling oral disintegrating tablets for ED, including those using a combination of Tadalafil and Sildenafil (the active ingredient in Viagra). Additionally, because our Mango ED product is being specially compounded for the customer by a pharmacist with a physician’s prescription and because the ingredients for our Mango ED product will be publicly disclosed, this product formula can be replicated by other companies. Because our ED product has not been, and will not be, approved by the FDA, our product has not had the benefit of the FDA’s clinical trial protocol which seeks to prevent the possibility of serious patient injury and death. If this were to occur, we could be subject to litigation and governmental action, which could result in costly litigation, significant fines, judgments or penalties. We currently anticipate using approximately $1.8 million of the net proceeds of this offering to finance the marketing and operational expenses associated with the planned marketing of our Mango ED product. We launched our website in mid-November 2022. To date, we have sold only a small amount of products and generated only nominal revenues. We plan to market and seek to sell commercial quantities of our Mango ED product in the first quarter of 2023 following this offering. Mango has been formulated as a Rapid Dissolve Tablet (“RDT”) using a sublingual (applied under the tongue) delivery system to bypass the stomach and liver. It is a generally established principle that sublingual drug absorption through the oral mucosa is generally faster than drug absorption through the gastrointestinal tract. This is because sublingual drugs that are absorbed through the oral mucosa directly enter the systemic circulation, bypassing the gastrointestinal tract and first-pass metabolism in the liver (see H. Zhang et al., Oral mucosal drug delivery: clinical pharmacokinetics and therapeutic applications, 41 Clin Pharmacokinet 661, 662 (2002). Though the active ingredients that comprise our Mango product are meant to treat ED – an issue that according to a 2018 study published in The Journal of Sexual Medicine has been estimated to affect over one-third of today’s men’s population (with prevalence increasing with age) – we are also aiming to brand ourselves as a lifestyle company marketed to men seeking enhanced sexual vitality, performance, and overall mood and confidence. Mango is expected to be sold exclusively online via our recently launched website at www.MangoRX.com. Our principal executive offices are located at 15110 N. Dallas Parkway, Suite 600, Dallas, Texas 75248, and our telephone number is (214) 242-9619. Our principal website address is www.mangorx.com. The Company was formed as a Texas corporation on October 7, 2021. At the time of the formation of the Company, the Company was wholly-owned by American International. Jacob D. Cohen, our Chairman and Chief Executive Officer, holds majority voting control over American International and also serves as the Chief Executive Officer, President and a member of the Board of Directors of American International. American International formed the Company with the intent of focusing on developing, marketing and selling a variety of men’s wellness products and services via a telemedicine platform. On June 16, 2022, American International entered into and closed the transactions contemplated by a Stock Purchase Agreement (the “SPA”) with Cohen Enterprises, Inc. (“Cohen Enterprises”), which is owned by Mr. Cohen, the Chairman and Chief Executive Officer of the Company, and who is also the majority shareholder of the Company. American International determined to divest its interests in the Company in order to focus on developing its pharmacy business through its 51% ownership of Epiq Scripts, which entity the Company has entered into the Master Services Agreement.
AI Analysis | Feedback
Hims & Hers for compounded ED treatments.
AI Analysis | Feedback
- Telehealth Services: Connects consumers to licensed healthcare professionals for virtual consultations, with an initial focus on men's wellness and erectile dysfunction.
- Online Pharmacy Access: Provides customers access to a licensed pharmacy for online fulfillment and distribution of prescribed medications.
- Mango ED Product: A compounded, rapid-dissolve sublingual tablet for erectile dysfunction, containing Tadalafil, Oxytocin, and L-Arginine.
AI Analysis | Feedback
Mangoceuticals (MGRX) sells primarily to **individuals** through its website, www.MangoRX.com, offering men's wellness telemedicine services and products. Based on the provided description, the company serves the following categories of customers:
Men experiencing Erectile Dysfunction (ED): This is the primary target demographic for their "Mango" ED product, aimed at addressing a condition estimated to affect a significant portion of the male population.
Men seeking enhanced sexual vitality and performance: The company also positions itself as a lifestyle brand for men looking to improve their sexual health beyond just clinical ED, focusing on vitality and performance.
Men interested in overall mood and confidence improvements related to sexual health: As part of its lifestyle branding, Mangoceuticals targets men who seek better mood and confidence, recognizing the link between sexual health and overall well-being.
AI Analysis | Feedback
Epiq Scripts
AI Analysis | Feedback
Jacob D. Cohen - Chief Executive Officer and Chairman
Jacob D. Cohen is a serial entrepreneur with over 20 years of experience in investment banking and capital markets, having started and grown multiple companies across various sectors, including marketing, advertising, healthcare, IT, and financial services. Prior to co-founding Mangoceuticals, Inc., he was a co-founder and managing partner of several boutique investment bank and strategic advisory firms, where he advised companies on raising capital in both private and public markets. He previously served as the Chief Financial Officer of The Renewed Group, Inc. from 2010 through 2013, and as Executive Vice President and Controller of Metiscan, Inc. from 2008 to 2010, where he restructured and operated the company and its subsidiaries and raised over $8 million in equity financing. He was also President and Chief Executive Officer of Shoreline Employment Services, Inc., a Metiscan subsidiary. Mr. Cohen is also the CEO of Cohen Enterprises, Inc., which acquired control of MGRX in 2022, and Ronin Equity Partners, Inc., both private investment companies.
Eugene M. Johnston - Chief Financial Officer
Eugene M. Johnston was appointed as Chief Financial Officer of Mangoceuticals, Inc. on October 1, 2022. In this role, he is responsible for the company's financial planning, risk management, and reporting, overseeing all financial activities, including budgeting, forecasting, and investment strategies. He possesses extensive expertise in corporate finance, accounting, and capital markets, gained through a distinguished career in the financial sector where he held senior financial positions at prominent organizations before joining Mangoceuticals.
Amanda Hammer - Chief Operating Officer
Amanda Hammer joined the MangoRx team in late 2022 and has been instrumental in launching and optimizing MangoRx's e-commerce platform. She oversees the company's day-to-day administrative and operational functions, bringing a wealth of experience in operational management, process optimization, and team leadership. Prior to Mangoceuticals, she had a four-year tenure at D Magazine Partners, a Dallas-based multimedia company, where she rose to become the company's first Chief Operations Officer.
Antonios Isaac - President and Director
Antonios Isaac serves as President and a Director of Mangoceuticals, Inc. In his capacity as President, he plays a pivotal role in guiding the company's operational direction and fostering its growth initiatives, and as a Director, he contributes to strategic decision-making and corporate governance. His leadership focuses on driving operational efficiency and fostering strategic partnerships.
Jonathan Arango - Director
Jonathan Arango serves as a Director of Mangoceuticals, Inc. He plays a multifaceted role, contributing significantly to the company's governance and strategic direction, which includes corporate governance, legal compliance, and the execution of strategic initiatives.
AI Analysis | Feedback
Key Risks to Mangoceuticals (MGRX)
- Regulatory Non-Compliance and Product Safety: Mangoceuticals' "Mango" ED product has not been, and will not be, approved by the FDA. Instead, the company plans to produce and sell its products under an exemption provided by Section 503A of the Federal Food, Drug, and Cosmetic Act. The company states it is not aware of any clinical studies involving the sublingual administration of tadalafil at the doses they provide or the compounding of tadalafil, oxytocin, and L-arginine to treat ED, as contemplated by their product. The absence of FDA approval means the product has not benefited from the FDA’s clinical trial protocol, which seeks to prevent serious patient injury and death, exposing the company to significant risks of costly litigation, governmental action, fines, judgments, or penalties.
- Intense Competition and Product Replicability: The company explicitly states that because its Mango ED product is specially compounded for the customer with publicly disclosed ingredients, the product formula can be replicated by other companies. Mangoceuticals is also aware of other companies currently selling oral disintegrating tablets for ED, some using a combination of Tadalafil and Sildenafil, indicating a competitive market that could challenge their ability to gain and maintain market share.
- Limited Operating History and Nominal Revenues: Mangoceuticals launched its website in mid-November 2022 and planned to market and seek to sell commercial quantities of its Mango ED product in the first quarter of 2023. To date, the company has sold only a small amount of products and generated only nominal revenues, highlighting the risks associated with an early-stage company that has not yet established significant market traction or a consistent revenue stream.
AI Analysis | Feedback
The ability for Mangoceuticals' core Mango ED product formula to be replicated by other companies, combined with the explicit awareness of existing competitors already selling similar oral disintegrating tablets for ED, poses a clear emerging threat. As Mangoceuticals attempts to market and sell its product, any success in generating demand for its specific compounded sublingual ED treatment can be immediately capitalized upon by current and new competitors. These competitors can easily replicate the publicly disclosed formula without significant research and development costs or intellectual property barriers, leading to rapid market commoditization and intense competitive pressure for market share and pricing.AI Analysis | Feedback
The addressable markets for Mangoceuticals' main products and services in the U.S. are as follows:
- Erectile Dysfunction (ED) Drugs Market: The U.S. erectile dysfunction drugs market was valued at approximately USD 1.09 billion in 2024 and is projected to reach around USD 2.55 billion by 2034, demonstrating a compound annual growth rate (CAGR) of 8.87% from 2025 to 2034.
- Telemedicine Market: The U.S. telemedicine market size was valued at USD 81 billion in 2024. This market is anticipated to expand from USD 94.3 billion in 2025 to USD 395.6 billion by 2034, with a CAGR of 17.3%.
AI Analysis | Feedback
Expected Revenue Growth Drivers for Mangoceuticals (MGRX)
- Growth in customers utilizing the MangoRX.com telehealth platform and associated pharmacy services: Mangoceuticals plans to connect consumers to licensed healthcare professionals via its recently launched website, MangoRX.com, for telehealth consultations and access to a licensed pharmacy for online fulfillment of prescribed medications. Increased adoption of these telehealth services is expected to drive customer growth and associated revenue.
- Successful commercialization and sales growth of the "Mango" Erectile Dysfunction (ED) product: The company has developed and is actively preparing to commercially market its new "Mango" ED product. With anticipated marketing and operational investments, increased sales volume of this product, available in two dosage levels and compounded under Section 503A of the FD&C Act, is a key expected driver of revenue growth.
- Expansion of brand positioning as a lifestyle company for men's sexual vitality and overall well-being: Beyond treating ED, Mangoceuticals aims to brand itself as a lifestyle company targeting men seeking enhanced sexual vitality, performance, and overall mood and confidence. This broader market appeal and branding strategy could attract a wider customer base and drive revenue growth.
- Increased market penetration within the growing men's wellness telemedicine sector: Mangoceuticals has identified men’s wellness telemedicine services and products, particularly those related to ED, as a growing sector. The company's strategic focus on this expanding market segment and its online-exclusive sales model via MangoRX.com are expected to contribute to increased market share and revenue.
AI Analysis | Feedback
Share Issuance
- Mangoceuticals anticipates using approximately $1.8 million of the net proceeds from an offering to finance marketing and operational expenses for its Mango ED product.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Mangoceuticals Earnings Notes | 12/16/2025 | |
| With Mangoceuticals Stock Sliding, Have You Assessed The Risk? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to MGRX.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 02282026 | QDEL | QuidelOrtho | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
| 02272026 | CHE | Chemed | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 02272026 | LLY | Eli Lilly | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | 0.0% | 0.0% | 0.0% |
| 02202026 | HAE | Haemonetics | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 3.5% | 3.5% | 0.0% |
| 02132026 | IQV | IQVIA | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 7.1% | 7.1% | -3.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 3.72 |
| Mkt Cap | 0.2 |
| Rev LTM | 195 |
| Op Inc LTM | -7 |
| FCF LTM | -2 |
| FCF 3Y Avg | 1 |
| CFO LTM | 8 |
| CFO 3Y Avg | 12 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 27.1% |
| Rev Chg 3Y Avg | 41.6% |
| Rev Chg Q | 28.4% |
| QoQ Delta Rev Chg LTM | 0.8% |
| Op Mgn LTM | -3.4% |
| Op Mgn 3Y Avg | -9.2% |
| QoQ Delta Op Mgn LTM | -0.7% |
| CFO/Rev LTM | 4.2% |
| CFO/Rev 3Y Avg | 7.1% |
| FCF/Rev LTM | -1.0% |
| FCF/Rev 3Y Avg | 1.0% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 0.2 |
| P/S | 1.9 |
| P/EBIT | -0.3 |
| P/E | 11.3 |
| P/CFO | 14.7 |
| Total Yield | 2.9% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 0.6% |
| D/E | 0.0 |
| Net D/E | -0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 33.5% |
| 3M Rtn | -31.6% |
| 6M Rtn | -66.8% |
| 12M Rtn | -33.5% |
| 3Y Rtn | 95.6% |
| 1M Excs Rtn | 32.0% |
| 3M Excs Rtn | -28.6% |
| 6M Excs Rtn | -61.1% |
| 12M Excs Rtn | -53.4% |
| 3Y Excs Rtn | 38.2% |
Price Behavior
Price Behavior
| Market Price | $0.49 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 03/21/2023 | |
| Distance from 52W High | -82.2% | |
| 50 Days | 200 Days | |
| DMA Price | $0.42 | $1.38 |
| DMA Trend | down | down |
| Distance from DMA | 15.7% | -64.8% |
| 3M | 1YR | |
| Volatility | 287.3% | 182.0% |
| Downside Capture | 3.08 | 1.86 |
| Upside Capture | 463.88 | 50.91 |
| Correlation (SPY) | 28.3% | 16.0% |
MGRX Betas & Captures as of 2/28/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 5.36 | 1.68 | 0.74 | 2.00 | 1.11 | 0.16 |
| Up Beta | 7.52 | 3.89 | 2.07 | 0.50 | 0.69 | 0.26 |
| Down Beta | -2.87 | -1.04 | -0.84 | 3.93 | 1.72 | -1.01 |
| Up Capture | 1067% | 88% | -172% | -72% | -17% | -5% |
| Bmk +ve Days | 9 | 20 | 31 | 70 | 142 | 431 |
| Stock +ve Days | 9 | 16 | 26 | 53 | 112 | 323 |
| Down Capture | 351% | 245% | 230% | 250% | 146% | 110% |
| Bmk -ve Days | 12 | 21 | 30 | 54 | 109 | 320 |
| Stock -ve Days | 11 | 24 | 33 | 68 | 129 | 393 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with MGRX | |
|---|---|---|---|---|
| MGRX | -79.6% | 182.2% | -0.03 | - |
| Sector ETF (XLV) | 0.3% | 17.6% | -0.13 | 1.4% |
| Equity (SPY) | 14.5% | 18.9% | 0.59 | 16.0% |
| Gold (GLD) | 50.2% | 27.7% | 1.46 | 5.1% |
| Commodities (DBC) | 17.8% | 17.6% | 0.85 | -2.8% |
| Real Estate (VNQ) | 0.4% | 16.4% | -0.15 | 18.6% |
| Bitcoin (BTCUSD) | -23.7% | 44.2% | -0.49 | 7.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with MGRX | |
|---|---|---|---|---|
| MGRX | -61.5% | 165.0% | -0.22 | - |
| Sector ETF (XLV) | 6.0% | 14.5% | 0.23 | 2.6% |
| Equity (SPY) | 11.8% | 17.0% | 0.54 | 8.5% |
| Gold (GLD) | 20.7% | 17.7% | 0.96 | 5.0% |
| Commodities (DBC) | 11.6% | 18.9% | 0.50 | -1.5% |
| Real Estate (VNQ) | 3.0% | 18.8% | 0.07 | 8.2% |
| Bitcoin (BTCUSD) | 4.0% | 56.6% | 0.29 | 3.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with MGRX | |
|---|---|---|---|---|
| MGRX | -38.0% | 165.0% | -0.22 | - |
| Sector ETF (XLV) | 9.7% | 16.5% | 0.48 | 2.6% |
| Equity (SPY) | 14.0% | 17.9% | 0.67 | 8.5% |
| Gold (GLD) | 13.3% | 15.8% | 0.70 | 5.0% |
| Commodities (DBC) | 8.2% | 17.6% | 0.39 | -1.5% |
| Real Estate (VNQ) | 4.7% | 20.7% | 0.19 | 8.2% |
| Bitcoin (BTCUSD) | 66.4% | 66.8% | 1.06 | 3.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/15/2024 | -2.7% | -12.3% | -17.9% |
| 10/19/2023 | 25.0% | 10.3% | -36.7% |
| SUMMARY STATS | |||
| # Positive | 1 | 1 | 0 |
| # Negative | 1 | 1 | 2 |
| Median Positive | 25.0% | 10.3% | |
| Median Negative | -2.7% | -12.3% | -27.3% |
| Max Positive | 25.0% | 10.3% | |
| Max Negative | -2.7% | -12.3% | -36.7% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 11/14/2025 | 10-Q |
| 06/30/2025 | 08/14/2025 | 10-Q |
| 03/31/2025 | 05/15/2025 | 10-Q |
| 12/31/2024 | 03/20/2025 | 10-K |
| 09/30/2024 | 11/14/2024 | 10-Q |
| 06/30/2024 | 08/14/2024 | 10-Q |
| 03/31/2024 | 05/15/2024 | 10-Q |
| 12/31/2023 | 04/01/2024 | 10-K |
| 09/30/2023 | 10/27/2023 | 10-Q |
| 06/30/2023 | 07/28/2023 | 10-Q |
| 03/31/2023 | 05/10/2023 | 10-Q |
| 12/31/2022 | 02/21/2023 | S-1/A |
| 09/30/2022 | 01/13/2023 | S-1 |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Johnston, Eugene M | CFO | Direct | Sell | 12172025 | 1.17 | 3,333 | 3,884 | 139,836 | Form |
| 2 | Johnston, Eugene M | CFO | Direct | Sell | 12112025 | 1.20 | 5,000 | 5,975 | 147,383 | Form |
| 3 | Johnston, Eugene M | CFO | Direct | Sell | 12092025 | 1.13 | 10,000 | 11,280 | 144,760 | Form |
| 4 | Hamilton, Alex P | Direct | Sell | 11262025 | 1.22 | 125,000 | 152,875 | 4,077 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.